---
title: "Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287276376.md"
description: "Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News"
datetime: "2026-05-21T13:40:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287276376.md)
  - [en](https://longbridge.com/en/news/287276376.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287276376.md)
generator: "portal-rs"
---

# Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News

### Related Stocks

- [ZNTL.US](https://longbridge.com/en/quote/ZNTL.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [Zentalis to Present Phase 1b MUIR Data: 39% ORR, 7.3‑month PFS; 50% ORR at 250 mg Cohort](https://longbridge.com/en/news/287276070.md)
- [Zentalis To Present Part 1 Phase 1b MUIR Trial Results Of Azenosertib At ASCO 2026](https://longbridge.com/en/news/287345181.md)
- [Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC](https://longbridge.com/en/news/298830378.md)
- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [09:28 ETNew LabCentral Program "The Loop" Offers International Biotech Start-Ups and Partner Organizations Curated Learnings Directly from U.S. Market](https://longbridge.com/en/news/298328140.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**